作者
Sjoukje JC Van der Stegen, David M Davies, Scott Wilkie, Julie Foster, Jane K Sosabowski, Jerome Burnet, Lynsey M Whilding, Roseanna M Petrovic, Sadaf Ghaem-Maghami, Stephen Mather, Jean-Pierre Jeannon, Ana C Parente-Pereira, John Maher
发表日期
2013/11/1
期刊
The Journal of Immunology
卷号
191
期号
9
页码范围
4589-4598
出版商
American Association of Immunologists
简介
The ErbB network is dysregulated in many solid tumors. To exploit this, we have developed a chimeric Ag receptor (CAR) named T1E28z that targets several pathogenetically relevant ErbB dimers. T1E28z is coexpressed with a chimeric cytokine receptor named 4αβ (combination termed T4), enabling the selective expansion of engineered T cells using IL-4. Human T4+ T cells exhibit antitumor activity against several ErbB+ cancer types. However, ErbB receptors are also expressed in several healthy tissues, raising concerns about toxic potential. In this study, we have evaluated safety of T4 immunotherapy in vivo using a SCID beige mouse model. We show that the human T1E28z CAR efficiently recognizes mouse ErbB+ cells, rendering this species suitable to evaluate preclinical toxicity. Administration of T4+ T cells using the iv or intratumoral routes achieves partial tumor regression without clinical or …
引用总数
2013201420152016201720182019202020212022202320242810718161115171683